Selected characteristics of 24 patients undergoing allogeneic peripheral HSCT
| . | Patients with early IPS-related death (n = 9) . | All others (n = 15) . |
|---|---|---|
| Age, median (range), y | 43 (19-48) | 40 (24-60) |
| Sex, no. | ||
| Male | 5 | 6 |
| Female | 4 | 9 |
| Stem cell source, no. | ||
| Histocompatible family member | 6 | 11 |
| Unrelated donor | 3 | 4 |
| Diagnosis, no. | ||
| CML (stable phase) | 5 | 8 |
| AML | ||
| In first remission | 2 | 1 |
| In subsequent remission | 1 | 2 |
| RA/RARS | 0 | 1 |
| RAEB, RAEB-T | 1 | 2 |
| CLL | 0 | 1 |
| Acute GVHD grade,33 no. (%) | 2 (22) | 11 (73) |
| 0-I | 7 | 13 |
| II-IV | 2 | 2 |
| 0-A | 7 | 8 |
| B-D | 2 | 7 |
| Veno-occlusive disease, no. (%) | 7 (78) | 5 (33) |
| Death within 1 y after transplantation, no. (%) | 9 (100) | 5 (33) |
| Survival after transplantation, median (range), d | 28 (20-50) | 1124 (73-≥1462) |
| . | Patients with early IPS-related death (n = 9) . | All others (n = 15) . |
|---|---|---|
| Age, median (range), y | 43 (19-48) | 40 (24-60) |
| Sex, no. | ||
| Male | 5 | 6 |
| Female | 4 | 9 |
| Stem cell source, no. | ||
| Histocompatible family member | 6 | 11 |
| Unrelated donor | 3 | 4 |
| Diagnosis, no. | ||
| CML (stable phase) | 5 | 8 |
| AML | ||
| In first remission | 2 | 1 |
| In subsequent remission | 1 | 2 |
| RA/RARS | 0 | 1 |
| RAEB, RAEB-T | 1 | 2 |
| CLL | 0 | 1 |
| Acute GVHD grade,33 no. (%) | 2 (22) | 11 (73) |
| 0-I | 7 | 13 |
| II-IV | 2 | 2 |
| 0-A | 7 | 8 |
| B-D | 2 | 7 |
| Veno-occlusive disease, no. (%) | 7 (78) | 5 (33) |
| Death within 1 y after transplantation, no. (%) | 9 (100) | 5 (33) |
| Survival after transplantation, median (range), d | 28 (20-50) | 1124 (73-≥1462) |
Patients with and without early fatal IPS did not differ significantly with respect to age, sex, stem cell source, underlying disease, or conditioning regimen.
CML indicates chronic myelogenous leukemia; AML, acute myelogenous leukemia; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-T, RAEB in transformation; CLL, chronic lymphocytic leukemia.